DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell–mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Wudhikarn, Kitsada, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Devlin, Sean M., Batlevi, Connie Lee, Shah, Gunjan L., Scordo, Michael, Palomba, Maria Lia, Dahi, Parastoo B., Sauter, Craig S., Santomasso, Bianca D., Mead, Elena, Perales, Miguel-Angel
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362382/
https://ncbi.nlm.nih.gov/pubmed/32614964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001972
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky